Cytopia is beginning enrollment for its Phase Ib/II study of CYT997, its vascular-disrupting anticancer agent, in patients with an aggressive form of brain cancer known as glioblastoma multiforme (GBM).
This trial follows the company’s Phase I safety study for intravenous CYT997, in which a prolonged delay in tumor growth was observed in seven of the study’s 31 advanced cancer patients. The new study will investigate the drug in combination with two other marketed anti-cancer agents in roughly 30 patients at clinical centers in Australia and other countries.
GBM is treated by surgical resection or chemotherapy with radiation, but it often recurs in patients. GBM tumors are highly vascular and heavily dependent on their own abnormal blood supply for growth, which may make them susceptible to destruction by an anti-vascular agent such as this product, Cytopia said.